Stage-specific embryonic antigen 4 (SSEA-4)

Stage-specific embryonic antigen 4 (SSEA-4) is a sialylated glycosphingolipid belonging to the globo-series family, widely recognized as a hallmark marker for undifferentiated human embryonic stem cells and induced pluripotent stem cells [5, 7, 10]. It is synthesized through the sialylation of SSEA-3, a process primarily mediated by the sialyltransferase ST3GAL2 [8, 11]. While its expression is highly restricted in normal adult tissues—found only on select populations like mesenchymal stem cells and certain epithelial cells—it is significantly overexpressed in various aggressive malignancies, including glioblastoma, triple-negative breast cancer, and non-small cell lung cancer [1, 4, 11]. Functionally, SSEA-4 is involved in promoting the epithelial-to-mesenchymal transition (EMT), enhancing tumor cell adhesion to the extracellular matrix, and facilitating invasion and metastasis [8, 9, 11]. Due to its prominent role in cancer progression and chemoresistance, SSEA-4 is being actively investigated as a therapeutic target for monoclonal antibodies (e.g., MC813-70), vaccines, and CAR T cell therapies [1, 4, 11]. However, the clinical development of SSEA-4-targeted agents faces challenges regarding on-target/off-tumor toxicities, as the antigen is also present on some normal progenitor cells in the bone marrow and lungs [4, 15].

Other names

Sialyl-galactosylgloboside [13]Sialyl-Gb5Cer [9, 12]SGG [3, 9]MSGG [3, 9]Stage-specific embryonic antigen-4 [5, 6]

Drugs targeting SSEA-4 typically act through immune-mediated mechanisms such as complement-dependent cytotoxicity (CDC) [1, 2, 11], antibody-dependent cellular cytotoxicity (ADCC), or direct T-cell mediated lysis in the case of CAR T therapies [4]. Additionally, small molecules like Tacrolimus (FK-506) can inhibit the trafficking of SSEA-4 to the cell surface by interfering with its interaction with the chaperone protein FKBP4 [11, 12].